Dr. Qi Zhang is a research associate professor in School of Medicine, Tsinghua University. She graduated from Martin-Luther University, Halle-Wittenberg Germany with a Ph.D. of Biochemistry/Biotechnology. Her research focuses on pathogenesis, antibody drug and vaccine development in the field of emerging and re-emerging human viral pathogens such as SARS‑CoV‑1/2, Ebola virus and other major viral infectious diseases. Dr. Zhang’s research aims to characterize protective antibody immunity in infected humans and rational design of effective vaccines and therapies against the viral infection. Together with Shenzhen 3rd People’s Hospital and Brii Biosciences, Dr. Zhang in Prof. Linqi Zhang’s team has developed an antibody combination therapy (amubarvimab/romlusevimab) that demonstrated 80% efficacy in reducing hospitalization and death among the high-risk population in a NIH-sponsored multicenter, double-blind, randomized, placebo-controlled study. The combination therapy was the first approved by China National Medical Products Administration on December 9, 2021 to treat adults and pediatric COVID-19 patients. Dr. Zhang has also been actively collaborating with Walvax biotechnology in developing COVID-19 nasal vaccines. Her research results have been published in Nature, Immunology, Nature Immunology, Nature Communications and other top-tier journals, with more than 7700 citations.